Gossamer Bio FY2025 EPS Forecast Raised by Cantor Fitzgerald

Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Investment analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Gossamer Bio in a research report issued to clients and investors on Monday, March 24th. Cantor Fitzgerald analyst O. Brayer now expects that the company will post earnings of ($0.70) per share for the year, up from their prior forecast of ($0.72). The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.

A number of other research firms also recently commented on GOSS. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Gossamer Bio in a report on Tuesday, March 18th. Wedbush reaffirmed an "outperform" rating and set a $4.00 target price on shares of Gossamer Bio in a research report on Friday, March 14th.

Gossamer Bio Stock Up 0.9 %

NASDAQ GOSS traded up $0.01 on Wednesday, reaching $1.17. The stock had a trading volume of 1,109,587 shares, compared to its average volume of 1,565,723. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.55. The business has a 50 day moving average price of $1.19 and a 200 day moving average price of $0.99. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 3.64. The company has a market capitalization of $265.85 million, a price-to-earnings ratio of -3.66 and a beta of 1.86.

Gossamer Bio (NASDAQ:GOSS - Get Free Report) last posted its quarterly earnings results on Tuesday, March 18th. The company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The company had revenue of $9.38 million for the quarter, compared to analyst estimates of $7.02 million.

Remove Ads

Hedge Funds Weigh In On Gossamer Bio

Institutional investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. boosted its position in shares of Gossamer Bio by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,241,979 shares of the company's stock valued at $1,123,000 after acquiring an additional 13,902 shares during the period. Graham Capital Management L.P. acquired a new stake in Gossamer Bio in the 4th quarter worth $32,000. Geode Capital Management LLC increased its holdings in shares of Gossamer Bio by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,250,461 shares of the company's stock worth $2,037,000 after purchasing an additional 38,084 shares during the period. Bank of America Corp DE raised its position in shares of Gossamer Bio by 107.2% during the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company's stock valued at $77,000 after buying an additional 43,866 shares during the last quarter. Finally, Fullcircle Wealth LLC acquired a new position in shares of Gossamer Bio during the fourth quarter valued at about $43,000. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.